Safety and early efficacy of involved-field SBRT for nodal oligo-recurrent prostate cancer
With the widespread adoption of PSMA agents, NORs are likely to increase. The optimal combination of local and systemic therapy in this population is unknown. With a favorable toxicity profile, IF-SBRT represents a safe and convenient local therapy treatment option for an elderly patient population. Patient- and treatment-related factors such as a large number of involved nodes and/or abdominal treatment may be associated with an increased risk of GI toxicity.
Authors
- Michael Carrasquilla (ORCID: https://orcid.org/0000-0003-0957-0248)
- Malika Danner
- Mary-Kate Lawlor
- Michael H. Creswell
- Timothy O’Connor (ORCID: https://orcid.org/0000-0001-5848-3592)
- Simeng Suy
- Sean P. Collins (ORCID: https://orcid.org/0000-0002-2305-9836)
- Min Ji Koh (ORCID: https://orcid.org/0009-0004-1950-3860)
- Deepak Kumar (ORCID: https://orcid.org/0000-0001-6298-3565)
- Min Jung Koh (ORCID: https://orcid.org/0000-0001-9791-4463)
- Alan Zwart (ORCID: https://orcid.org/0000-0001-6834-9290)
- P. Pilkington
Institutions
- North Carolina Central University (US)
- University of Kansas (US)
- Georgetown University (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-17
- DOI
- https://doi.org/10.3389/fonc.2024.1434504
- Citations
- 2
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- National Institute on Minority Health and Health Disparities